# Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

> **NCT00154375** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 240 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Astrocytoma

## Interventions

- **DRUG:** Imatinib mesylate
- **DRUG:** Hydroxyurea

## Key facts

- **NCT ID:** NCT00154375
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2008-08
- **Final completion:** —
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2011-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00154375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00154375, "Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00154375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*